Koeller J M, Trump D L, Tutsch K D, Earhart R H, Davis T E, Tormey D C
Cancer. 1986 Jan 15;57(2):222-5. doi: 10.1002/1097-0142(19860115)57:2<222::aid-cncr2820570206>3.0.co;2-x.
Carboplatin (diammine [1,1-cyclobutanedicarboxylate(2-)-O,o']platinum) is a second generation platinum coordination complex. It has a spectrum of activity that is similar to that of cisplatin and is less nephrotoxic and emetogenic in experimental animals. Fifty-two 30-minute infusions of carboplatin were given to 20 evaluable patients with a variety of solid tumors. Maximum tolerated dose was 440 mg/m2. Thrombocytopenia (less than 100,000/mm3) occurred in six of seven patients; two patients experienced a leukocyte count less than 2000/mm3. Platelet and leukocyte count nadirs occurred on day 21. No nephrotoxicity was seen. Blood urea nitrogen, serum creatine levels, and creatinine clearances remained normal, and no consistent elevation of urinary beta 2-microglobulin, leucine aminopeptidase, or N-acetyl-beta-glucosaminidase occurred. Nausea and vomiting were mild to moderate. A single patient developed mild peripheral neuropathy. No auditory toxicity was noted. The recommended dose for Phase II studies is 400 mg/m2 every 28 days for good risk patients; heavily pretreated patients should receive 320 mg/m2.
卡铂（二氨[1,1 - 环丁烷二羧酸根（2 - ）-O，o']铂）是第二代铂配位络合物。它的活性谱与顺铂相似，在实验动物中肾毒性和致吐性较小。对20例可评估的患有各种实体瘤的患者进行了52次30分钟的卡铂输注。最大耐受剂量为440mg/m²。7例患者中有6例出现血小板减少（低于100,000/mm³）；2例患者白细胞计数低于2000/mm³。血小板和白细胞计数最低点出现在第21天。未观察到肾毒性。血尿素氮、血清肌酐水平和肌酐清除率保持正常，尿β2 - 微球蛋白、亮氨酸氨基肽酶或N - 乙酰 - β - 氨基葡萄糖苷酶未出现持续升高。恶心和呕吐为轻度至中度。1例患者出现轻度周围神经病变。未观察到听觉毒性。II期研究推荐剂量为，低风险患者每28天400mg/m²；预处理严重的患者应接受320mg/m²。
